View Older Stories View More Recent Stories

Jan 25, 2022 11:31AM Form SC 13G/A Surface Oncology, Inc. Filed by: Atlas Venture Fund IX, L.P.
Jan 25, 2022 11:29AM Form SC 13G/A Spero Therapeutics, Inc. Filed by: Atlas Venture Fund IX, L.P.
Jan 21, 2022 04:40PM Form SC 13D Vigil Neuroscience, Inc. Filed by: Atlas Venture Fund XII, L.P.
Jan 11, 2022 09:16PM Form 4 Vigil Neuroscience, Inc. For: Jan 11 Filed by: Atlas Venture Opportunity Fund I, L.P.
Jan 6, 2022 08:30PM Form 3 Vigil Neuroscience, Inc. For: Jan 06 Filed by: Atlas Venture Opportunity Fund I, L.P.
Jan 5, 2022 07:30AM Korro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine Through Its Pipeline of RNA Editing Programs
Dec 14, 2021 08:28PM Form 4 Ikena Oncology, Inc. For: Mar 30 Filed by: Atlas Venture Fund XI, L.P.
Dec 9, 2021 07:00AM K36 Therapeutics Launches with $30 Million Series A Financing from F-Prime Capital and Atlas Venture with Eight Roads Ventures
Dec 8, 2021 07:03AM Ikena Oncology Inc. (IKNA) Appoints Michelle Zhang as Chief Scientific Officer
Dec 8, 2021 07:00AM Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific Officer
Dec 8, 2021 07:00AM Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific Officer
Dec 1, 2021 06:30AM Curie Therapeutics Raises $75 Million Financing to Further its Mission of Transforming Cancer Care with Precision Radiopharmaceuticals
Nov 29, 2021 05:34PM Form 4 Day One Biopharmaceutica For: Nov 24 Filed by: Atlas Venture Fund XI, L.P.
Nov 29, 2021 06:30AM HotSpot Therapeutics Closes $100M Series C to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic
Nov 17, 2021 06:00AM Chroma Medicine Launches with $125M in Financing to Deliver on the Promise of Epigenetic Editing
Nov 5, 2021 04:43PM Form SC 13G Xilio Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Nov 5, 2021 04:38PM Form SC 13D Aerovate Therapeutics, Filed by: Atlas Venture Associates XII, LLC
Nov 4, 2021 10:56AM Form 13F-NT ATLAS VENTURE FUND VI For: Sep 30
Nov 4, 2021 10:55AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 4, 2021 10:53AM Form 13F-HR Atlas Venture Advisors, For: Sep 30
Nov 4, 2021 10:52AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 4, 2021 10:51AM Form 13F-HR Atlas Venture Associates For: Sep 30
Oct 26, 2021 05:02PM Form 4 Xilio Therapeutics, Inc. For: Oct 26 Filed by: Atlas Venture Fund XI, L.P.
Oct 21, 2021 08:49PM Form 3 Xilio Therapeutics, Inc. For: Oct 21 Filed by: Atlas Venture Fund XI, L.P.
Oct 14, 2021 06:30AM Rectify Pharmaceuticals Launches with $100 Million Series A Financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund
Oct 1, 2021 01:07PM Form D Atlas Venture Opportunit
Oct 1, 2021 07:00AM Atlas Venture Announces $300 Million Second Opportunity Fund
Sep 29, 2021 07:16PM Form 4 Generation Bio Co. For: Sep 27 Filed by: Atlas Venture Associates Opportunity I, LLC
Sep 28, 2021 08:15AM Nucleate launches nationwide to empower the next generation of biotech leaders
Sep 24, 2021 09:00PM Form 4 Generation Bio Co. For: Sep 22 Filed by: ATLAS VENTURE ASSOCIATES X, L.P.
Sep 22, 2021 06:59AM Endpoints News names the 11 most promising biotech startups of 2021
Sep 21, 2021 04:40PM Form 4 Generation Bio Co. For: Sep 17 Filed by: Atlas Venture Fund X, L.P.
Sep 15, 2021 10:00AM Kinaset Therapeutics Announces Dosing Underway in its Phase 1b Study of KN-002 in Healthy Volunteers and Asthma Patients
Sep 9, 2021 08:00AM Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
Sep 2, 2021 06:00AM Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases
Aug 31, 2021 07:00AM Versanis Bio Announces $70 Million Series A Financing to Advance Bimagrumab for the Treatment of Obesity
Aug 18, 2021 07:00AM Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases
Aug 17, 2021 08:30AM Remix Therapeutics Names Peter Smith, PhD, as President and Chief Executive Officer
Aug 12, 2021 10:42AM Form 4 Kymera Therapeutics, For: Aug 11 Filed by: Atlas Venture Associates X, LLC
Aug 11, 2021 11:42AM Form 13F-NT Atlas Venture Associates For: Jun 30
Aug 11, 2021 11:42AM Form 13F-NT ATLAS VENTURE FUND VI For: Jun 30
Aug 11, 2021 11:38AM Form 13F-NT Atlas Venture Associates For: Jun 30
Aug 11, 2021 11:38AM Form 13F-HR Atlas Venture Advisors, For: Jun 30
Aug 11, 2021 11:38AM Form 13F-HR Atlas Venture Associates For: Jun 30
Jul 15, 2021 04:34PM Form 4 Dyne Therapeutics, Inc. For: Jul 13 Filed by: Atlas Venture Fund XI, L.P.
Jul 13, 2021 06:00AM Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs
Jul 12, 2021 07:00AM Atlas Venture Welcomes Jodie Morrison as Venture Partner
Jul 8, 2021 07:30AM Life Edit Therapeutics Announces Newly Established Scientific Advisory Board
Jul 6, 2021 04:27PM Form 4 Aerovate Therapeutics, For: Jul 02 Filed by: Atlas Venture Associates XII, L.P.
Jun 29, 2021 08:47PM Form 3 Aerovate Therapeutics, For: Jun 29 Filed by: Atlas Venture Fund XII, L.P.
View More Recent Stories View Older Stories